Brainstem Circuit Modulation for PSP

🧫 Experiment Protocol ClinicalALSPSPhumanproposed

# Brainstem Circuit Modulation for PSP ## Background and Rationale Progressive Supranuclear Palsy (PSP) is a devastating neurodegenerative tauopathy characterized by selective brainstem circuit dysfunction, particularly affecting the pedunculopontine nucleus (PPN), locus coeruleus, and substantia nigra. Current therapeutic approaches remain largely symptomatic, with limited impact on disease progression or core brainstem-mediated symptoms including gait freezing, postural instability, and oculomotor dysfunction. This clinical trial represents a first-in-human investigation of targeted brainstem circuit modulation using advanced deep brain stimulation (DBS) paradigms specifically designed for PSP pathophysiology. The study employs a randomized, double-blind, sham-controlled design to evaluate the safety and efficacy of PPN-targeted DBS with novel stimulation parameters optimized for cholinergic circuit restoration. Unlike conventional DBS approaches developed for Parkinson's disease, this protocol utilizes low-frequency stimulation (20-40 Hz) with burst patterns designed to enhance cholinergic transmission and restore normal sleep-wake cycles. Key innovations include real-time circuit monitoring using local field potential recordings, personalized stimulation parameters based on individual brainstem imaging biomarkers, and integrated assessment of multiple brainstem functions including postural control, eye movements, and sleep architecture. The study will employ advanced neuroimaging including 7-Tesla MRI for precise targeting and diffusion tensor imaging to assess white matter tract integrity. Primary endpoints focus on validated PSP rating scales and quantitative gait analysis, while secondary measures include polysomnography, eye-tracking metrics, and neuroinflammatory biomarkers. This research addresses a critical unmet medical need and could establish brainstem circuit modulation as a disease-modifying therapy for PSP, with potential applications to other tauopathies affecting brainstem circuits. This experiment directly tests predictions arising from the following hypotheses: - **Orexin-Microglia Modulation Therapy** - **Hypocretin-Neurogenesis Coupling Therapy** - **Vocal Cord Neuroplasticity Stimulation** - **Circadian Rhythm Entrainment of Reactive Astrocytes** - **Circadian-Synchronized Proteostasis Enhancement** ## Experimental Protocol Phase 1 (Months 1-3): Recruit 60 PSP patients meeting MDS-PSP criteria, age 45-75, disease duration 2-8 years. Conduct comprehensive baseline assessments including PSP Rating Scale, quantitative gait analysis, polysomnography, and 7T MRI with brainstem-specific sequences. Phase 2 (Month 4): Perform stereotactic PPN-DBS implantation using real-time microelectrode recordings and intraoperative imaging guidance. Target coordinates: 5mm lateral, 5mm posterior, 2mm inferior to red nucleus. Implant quadripolar electrodes bilaterally with sensing capabilities. Phase 3 (Months 5-6): Randomize patients 1:1 to active stimulation (20-40 Hz, 60-90 μs pulse width, 2-4V amplitude with burst patterns) versus sham stimulation. Implement double-blind protocol with programmer blinding. Conduct weekly parameter optimization sessions using closed-loop algorithms based on local field potential feedback. Phase 4 (Months 7-18): Monthly assessments including PSP-RS, Unified Parkinson's Disease Rating Scale Part III, quantitative gait metrics using instrumented walkways, and sleep studies every 3 months. Collect cerebrospinal fluid biomarkers (tau, neurofilament light chain, neuroinflammatory markers) at baseline, 6, and 12 months. Phase 5 (Months 19-24): Open-label extension with optimized parameters for all patients, continued safety monitoring, and long-term efficacy assessment. Statistical analysis using mixed-effects models accounting for baseline severity and disease duration. ## Expected Outcomes - Primary efficacy outcome: 25-35% improvement in PSP Rating Scale total score in active stimulation group versus <10% improvement in sham group (p<0.01) at 12 months - Gait improvement: 40-50% reduction in freezing episodes and 20-30% improvement in stride length variability measured by quantitative gait analysis (effect size d=0.8-1.2) - Sleep architecture normalization: 50-60% increase in REM sleep percentage and 30-40% improvement in sleep efficiency scores on polysomnography compared to baseline - Oculomotor function enhancement: 35-45% improvement in vertical saccade velocity and 25-35% reduction in square wave jerks measured by eye-tracking (p<0.05) - Biomarker changes: 20-30% reduction in CSF neurofilament light chain levels and 15-25% decrease in tau phosphorylation markers indicating neuroprotective effects - Safety profile: <5% serious adverse events related to stimulation, with primary concerns being transient diplopia or gait worsening during parameter adjustment ## Success Criteria - • Primary efficacy threshold: ≥20% improvement in PSP Rating Scale compared to sham group with statistical significance (p<0.05) and effect size >0.6 - • Safety benchmark: <10% rate of serious stimulation-related adverse events and <15% surgical complication rate comparable to standard DBS procedures - • Functional improvement: ≥30% of patients achieving clinically meaningful improvement defined as ≥6-point PSP-RS reduction and objective gait parameter enhancement - • Sustained benefit: Maintenance of ≥15% improvement in primary outcomes at 24-month follow-up indicating durable therapeutic effect - • Biomarker correlation: Significant association between stimulation-induced clinical improvements and neuroinflammatory biomarker changes (r>0.4, p<0.05) - • Quality of life enhancement: ≥25% improvement in PSP Quality of Life Scale with patient and caregiver reported outcome measures supporting clinical findings

Source: wiki

🧫 Experiment Extras

🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found